USSN: 09/787,325

## **CLAIM AMENDMENTS**

Claims 97-98 (Cancelled)

100. 99. (Amended) A composition comprising an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a sulfonylurea, and wherein components of said composition synergistically reduce the HbA1c levels of a patient by at least about 10% after treatment for a period of at least about thirty days with said composition as compared to treatment with said anti-diabetic agent alone. The composition of claim 97, wherein said anti-diabetic agent comprises a type of anti-diabetic agent selected from the group consisting of thiazolidinediones, sulfonylureas, benzoic acid derivatives, and alpha-glucosidase inhibitors.

Claims 100-102 (Cancelled)

104. 103. (Amended) The composition according to claim 10399, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, tolbutamide, glycazide, glipizide, glyburide, or glimeperide.

Claims 104-114 (Cancelled)

116. 115. (Amended) A method for improving glucose metabolism, comprising treating a patient for at least about a thirty day period by administering a pharmaccutical composition comprising an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a sulfonylurea, and wherein said components of said composition synergistically reduce the Hb1AeHbA1c level forof said patient is reduced by at least about 10% after such treatment as compared to treatment with said anti-diabetic agent alone.

Claims 116-133 (Cancelled)